-
| Industry | Other |
|---|---|
| Sector | Other |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| ISIN | None |
| Dividend Yield | 0.0% |
|---|---|
| Beta | nan |
| Target Price | None |
| PE Ratio | None |
| Market Cap | 122M |
Xynomic Pharmaceuticals Holdings, Inc. a biopharmaceutical company, focuses on in-licensing, developing, and commercializing oncology drug candidates in China, the United States, and internationally. The company's pipeline primarily consists of three drug candidates, abexinostat, XP-105, and XP-102. Its lead drug candidate abexinostat is in pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin's lymphoma (as a single agent). The company's other clinical stage drug candidate XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors; and pre-clinical oncology drug candidate XP-102 (BI 882370) is a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for XYN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024